Bruker Group said it expects stimulus plans in the United States and around the globe to have a positive effect on its revenues for the rest of the year and beyond.
The Billerica-based scientific instruments maker made the claim in a presentation at the Goldman Sachs 30th Annual Global Healthcare Conference in New York.
Increased funding to federal agencies including the National Institutes of Health, NASA and the Dept. of Defense in the American Recovery and Reinvestment Act could positively affect more than 10 percent of the company’s domestic revenues, officials said. Similar efforts in Germany, the European Union, China, Japan and elsewhere could boost more than 20 percent of the company’s revenues.
Bruker said it expects any uptick to surface during the second half of 2009, with the strongest results coming in 2010 and carrying over into 2011.
The company posted $230 million in sales during the three months ended March 31, down just more than 3 percent from $238 million during the 2008 first quarter.